Medical device CRO Genae buys health data management company

data infographic
Medical device CRO Genae has bought Hilbert Paradox (HPX) to strengthen its recently launched data management platform. (Pixabay)

Belgium-headquartered medical device CRO Genae has bought Hilbert Paradox (HPX) to strengthen its data management platform.

HPX’s solution uses computing power, data analytics and artificial intelligence to help collect, store and analyze health data. It also helps clients examine and increase the value of their health datasets—an ability known as data equity—for better patient treatments.

HPX’s services will be folded into Genae’s digital health division and incorporated into its Staicy platform.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Genae launched its health data management system Staicy last September. Based on Genae’s two-decade experience in electronic data capture and its clinical research expertise gathered from about 450 clinical trials, Staicy supports data management through analysis, visualization and correlation of a variety of data.

“It enables integration of otherwise isolated data silos and eClinical systems, such as CTMS platforms, ePRO and hospital files,” said Genae CEO Bart Segers at the time.

“Staicy is all about visual data discovery for clinical research, and HPX’s technology revolves around the same for digital health data,” Segers told FierceCRO.  

Sergers said the HPX technology is able to process large data volumes from connected and diagnostic devices, websites and applications in the field of genomics, biosensors and wearables.

“The rationale for integrating technology like the one from HPX is captured in future preventive requirements; moving from disease to health management in which the patient decides about what to share with whom,” he said.

Suggested Articles

The FDA has cleared Drawbridge Health’s blood collection device designed to help monitor long-term blood sugar levels in people with diabetes.

FierceMedTech Fierce 15 winner 10x Genomics announced its plans for a $100 million IPO, on the Nasdaq using the symbol TXG.

Belgian devicemaker Miracor Medical received a breakthrough designation from the FDA for its treatment designed to limit the damage of a heart attack.